X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7218) 7218
Book Chapter (16) 16
Publication (5) 5
Conference Proceeding (4) 4
Dissertation (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nivolumab (6173) 6173
oncology (3959) 3959
immunotherapy (3302) 3302
humans (3111) 3111
ipilimumab (2146) 2146
pembrolizumab (2133) 2133
cancer (1949) 1949
melanoma (1919) 1919
chemotherapy (1615) 1615
docetaxel (1521) 1521
male (1454) 1454
female (1381) 1381
open-label (1327) 1327
middle aged (1197) 1197
metastasis (1183) 1183
aged (1178) 1178
lung cancer (1128) 1128
patients (1100) 1100
survival (1056) 1056
tumors (1012) 1012
immunology (997) 997
pd-1 (937) 937
care and treatment (929) 929
safety (895) 895
immune checkpoint (855) 855
cancer therapies (814) 814
therapy (803) 803
blockade (760) 760
adult (730) 730
apoptosis (730) 730
pd-l1 (721) 721
programmed cell death 1 receptor - antagonists & inhibitors (702) 702
multicenter (669) 669
clinical trials (662) 662
lymphocytes (660) 660
treatment outcome (654) 654
expression (629) 629
antibodies, monoclonal - therapeutic use (623) 623
antineoplastic agents, immunological - therapeutic use (617) 617
lung neoplasms - drug therapy (611) 611
prognosis (604) 604
immune checkpoint inhibitors (601) 601
metastatic melanoma (591) 591
cell lung-cancer (565) 565
pd-1 blockade (557) 557
biomarkers (547) 547
metastases (537) 537
research (532) 532
pd-1 protein (529) 529
analysis (526) 526
aged, 80 and over (525) 525
immunotherapy - methods (512) 512
advanced melanoma (505) 505
antineoplastic agents - therapeutic use (505) 505
respiratory system (505) 505
melanoma - drug therapy (497) 497
mutation (489) 489
adverse events (481) 481
antineoplastic agents, immunological - adverse effects (477) 477
lung cancer, non-small cell (474) 474
non-small cell lung cancer (473) 473
nivolumab - therapeutic use (470) 470
carcinoma, non-small-cell lung - drug therapy (461) 461
medicine, research & experimental (453) 453
medical prognosis (452) 452
pd-l1 protein (449) 449
drug therapy (425) 425
cell death (415) 415
ligands (401) 401
pharmacology & pharmacy (399) 399
lung neoplasms - pathology (394) 394
atezolizumab (392) 392
immune checkpoint inhibitor (385) 385
antibodies, monoclonal - adverse effects (384) 384
programmed cell death 1 receptor - immunology (384) 384
neoplasms. tumors. oncology. including cancer and carcinogens (379) 379
lymphocytes t (377) 377
combined nivolumab (373) 373
cytotoxicity (373) 373
medical research (372) 372
t-cells (372) 372
immunohistochemistry (368) 368
antibody (363) 363
efficacy (358) 358
review (358) 358
nivolumab - adverse effects (356) 356
anti-pd-1 (354) 354
case report (351) 351
antigens (347) 347
checkpoint inhibitors (346) 346
retrospective studies (344) 344
non-small cell lung carcinoma (342) 342
antibodies (341) 341
animals (333) 333
medicine & public health (333) 333
health aspects (327) 327
toxicity (324) 324
antibodies, monoclonal, humanized - therapeutic use (322) 322
antineoplastic combined chemotherapy protocols - therapeutic use (322) 322
b7-h1 antigen - antagonists & inhibitors (321) 321
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7029) 7029
French (102) 102
German (83) 83
Japanese (54) 54
Russian (26) 26
Korean (21) 21
Chinese (15) 15
Spanish (14) 14
Norwegian (7) 7
Czech (6) 6
Italian (5) 5
Portuguese (3) 3
Polish (2) 2
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | Rapid Communications
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 17, pp. 1668 - 1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited... 
CRITERIA | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 21, pp. 2020 - 2031
Journal Article
Oral oncology, ISSN 1368-8375, 2018, Volume 81, pp. 45 - 51
Journal Article
Journal of cellular physiology, ISSN 0021-9541, 2018, Volume 233, Issue 10, pp. 6337 - 6343
Journal Article
Cancer discovery, ISSN 2159-8290, 2018, Volume 8, Issue 7, pp. 822 - 835
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 1074 - 1074
Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability,... 
Abscopal effect | PD-L1 EXPRESSION | Radioimmunotherapy | METASTASES | Palliative radiotherapy | DOCETAXEL | CHEMOTHERAPY | LOCAL RADIOTHERAPY | RADIATION-THERAPY | PEMBROLIZUMAB | ONCOLOGY | Immunotherapy | Nivolumab | Non-small cell lung cancer | RESISTANCE | PD-1 | IPILIMUMAB | Antineoplastic Agents, Immunological - administration & dosage | Carcinoma, Non-Small-Cell Lung - radiotherapy | Prospective Studies | Follow-Up Studies | Humans | Lung Neoplasms - radiotherapy | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Radiation Dose Hypofractionation | Response Evaluation Criteria in Solid Tumors | Biomarkers, Tumor - analysis | Nivolumab - therapeutic use | Lung Neoplasms - therapy | Nivolumab - adverse effects | Antineoplastic Agents, Immunological - pharmacology | Antineoplastic Agents, Immunological - adverse effects | Carcinoma, Non-Small-Cell Lung - therapy | Nivolumab - pharmacology | Antineoplastic Agents, Immunological - therapeutic use | Progression-Free Survival | Quality of Life | B7-H1 Antigen - analysis | Combined Modality Therapy - methods | Cohort Studies | Nivolumab - administration & dosage | Immune response | Analysis | Oncology, Experimental | Radiation | Lung cancer, Small cell | Respiratory agents | Metastasis | Research | Lung cancer, Non-small cell | Radiotherapy | Cancer | Index Medicus
Journal Article
Clinical cancer research, ISSN 1557-3265, 2016, Volume 22, Issue 24, pp. 6051 - 6060
Purpose: Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor-related pneumonitis in advanced cancer... 
CELL LUNG-CANCER | UNTREATED MELANOMA | MAMMALIAN TARGET | DRUG-RELATED PNEUMONITIS | PEMBROLIZUMAB | ONCOLOGY | ADVANCED MELANOMA | RECEIVING NIVOLUMAB | LONG-TERM SAFETY | ADVERSE EVENTS | IPILIMUMAB | pembrolizumab | PD-1 inhibitor | nivolumab | pneumonitis | immune-related adverse event
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 974 - 10
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2019, Volume 37, Issue 6, pp. 481 - 489
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed... 
Hematopoietic Stem Cell Transplantation/adverse effects | Clinical Trial, Phase II | Humans | Middle Aged | Male | Journal Article | Research Support, N.I.H., Extramural | Young Adult | Time Factors | Treatment Failure | Aged, 80 and over | Adult | Female | Nivolumab/adverse effects | Chromosomes, Human, Pair 9 | Remission Induction | Disease Progression | Transplantation, Autologous/adverse effects | Lymphoma, Large B-Cell, Diffuse/drug therapy | Research Support, Non-U.S. Gov't | Progression-Free Survival | Multicenter Study | Aged | Programmed Cell Death 1 Receptor/antagonists & inhibitors | Antineoplastic Agents, Immunological/adverse effects | MULTICENTER | ONCOLOGY | PD-L1 | HODGKIN LYMPHOMA | OPEN-LABEL | OUTCOMES | DEATH LIGAND 1 | BLOCKADE | EXPRESSION | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, Large B-Cell, Diffuse - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - surgery | Nivolumab - therapeutic use | Nivolumab - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Transplantation, Autologous - adverse effects | Programmed Cell Death 1 Receptor - immunology | Lymphoma, Large B-Cell, Diffuse - genetics | ORIGINAL REPORTS
Journal Article